General MedicationsINJECTIONStandard
SYNERCID
QUINUPRISTIN; DALFOPRISTIN
Standard Dose
500MG
Max Dose
Refer to approved labeling
Primary Use
Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SYNERCID is listed in Drugs@FDA under application 050747 (NDA).
Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
Structured Monograph
Clinical summary
Approval overview SYNERCID is listed in Drugs@FDA under application 050747 (NDA). Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. Review priority: STANDARD Marketing status: Prescription Active ingredient QUINUPRISTIN; DALFOPRISTIN Form and strength INJECTABLE; INJECTION - 500MG Sponsor KING PHARMS Submission history Latest submission status date: 2017-06-16 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.